LTBP3

Across TCGA pan-cancer cohorts, LTBP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LTBP3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LTBP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LTBP3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where LTBP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.619	0.908	.001	93	view →
PDAC	DFS	Tertile	All	0.302	0.510	<.001	67	view →
GBM	DFS	Tertile	All	0.227	0.494	<.001	18	view →
UCEC	OS	Quartile	All	0.853	1.000	.013	6	view →
LSCC	OS	Median	All	0.803	0.926	.010	6	view →
LUAD	OS	Median	III,IV	0.683	0.212	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LTBP3–CCRCC (DFS)

Open the CCRCC breakdown →